



May 29, 2020

Transit Scientific  
Spencer Walker  
Director of Regulatory Affairs  
University of Utah  
10 North 1900 East, EHSL Rm. 22B  
Salt Lake City, Utah 84112

Re: K193420  
Trade/Device Name: XO Cross Support Catheter  
Regulation Number: 21 CFR 870.1250  
Regulation Name: Percutaneous catheter  
Regulatory Class: Class II  
Product Code: DQY

Dear Spencer Walker:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated May 6, 2020. Specifically, FDA is updating this SE Letter to reflect that changes have been implemented to your 510(k) Summary to remove proprietary information.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Lydia Glaw, OHT2: Office of Cardiovascular Devices, 301-796-1456, or [Lydia.glaw@fda.hhs.gov](mailto:Lydia.glaw@fda.hhs.gov).

Sincerely,

**Samuel G. Raben -S**

for Lydia Glaw  
Assistant Director  
DHT2C: Division of Coronary  
and Peripheral Intervention Devices  
OHT2: Office of Cardiovascular Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health



May 6, 2020

Transit Scientific  
Spencer Walker  
Director of Regulatory Affairs  
University of Utah  
10 North 1900 East, EHSL Rm. 22B  
Salt Lake City, Utah 84112

Re: K193420/S001  
Trade/Device Name: XO Cross Support Catheter  
Regulation Number: 21 CFR 870.1250  
Regulation Name: Percutaneous Catheter  
Regulatory Class: Class II  
Product Code: DQY  
Dated: April 3, 2020  
Received: April 6, 2020

Dear Spencer Walker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

**Lydia S.  
Glaw -S**

Digitally signed by  
Lydia S. Glaw -S  
Date: 2020.05.06  
16:33:27 -04'00'

Lydia Glaw  
Assistant Director  
DHT2C: Division of Coronary  
and Peripheral Interventional Devices  
OHT2: Office of Cardiovascular Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration <b>Indications for Use</b>	Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.
510(k) Number ( <i>if known</i> ) K193420	
Device Name  XO Cross Support Catheter	
Indications for Use ( <i>Describe</i> )  The XO Cross is a support catheter intended to guide and support a guidewire during access of the peripheral vasculature, allow for wire exchanges and provide a conduit for the delivery of saline solutions or diagnostic contrast agents.	
Type of Use (Select one or both, as applicable) <input checked="" type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D)   <input type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C)	
<b>CONTINUE ON A SEPARATE PAGE IF NEEDED.</b>	
<p>This section applies only to requirements of the Paperwork Reduction Act of 1995.</p> <p><b>*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*</b></p> <p>The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:</p> <p style="text-align: center;"> Department of Health and Human Services  Food and Drug Administration  Office of Chief Information Officer  Paperwork Reduction Act (PRA) Staff  <a href="mailto:PRASStaff@fda.hhs.gov">PRASStaff@fda.hhs.gov</a> </p> <p><i>“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”</i></p>	

### 510(k) Summary

<b>Submitter:</b>	Transit Scientific, LLC.
<b>Contact Person:</b>	Spencer Walker, MSC – Director Regulatory Affairs Center for Medical Innovation 10 North 1900 East, Rm 22B Salt Lake City, UT 84112 (801) 581-5080
<b>Date Prepared:</b>	December 5, 2019
<b>Trade Name:</b>	XO Cross Support Catheter
<b>Classification Name:</b>	Percutaneous Catheter 21 CFR §870.1250, Product Code DQY
<b>Device Class:</b>	Class II
<b>Predicate Device:</b>	<ul style="list-style-type: none"><li>• K082561 – Quick-Cross Extreme Support Catheter, Spectranetics Corporation, Inc.</li></ul>

### Device Description:

The XO Cross catheter is a single-lumen support catheter designed to support a guidewire during access of the peripheral vasculature, allowing for exchange of guidewires during vascular access procedures, and providing a conduit for the delivery of saline solutions or diagnostic contrast agents. The shaft and tip are both radiopaque to track the location of the *XO Cross* catheter within the vasculature, while under fluoroscopy. It is available in various lengths (90cm, 135cm, 150cm, 175cm) and ranges in diameter from 2 Fr (0.7 mm) to 4 Fr (1.35 mm) with a tapered polymer tip at its distal end.

### Indications for Use:

The XO Cross is a support catheter intended to guide and support a guidewire during access of the peripheral vasculature, allow for wire exchanges and provide a conduit for the delivery of saline solutions or diagnostic contrast agents.

### Comparative Analysis:

It has been demonstrated that the XO Cross catheter is comparable to the predicate device in intended use, fundamental scientific technology, design, principles of operation and functional performance evaluations. The XO Cross catheter has been fully assessed within the Transit Scientific Risk Management and Design Controls systems. All

necessary verification steps met pre-determined acceptance criteria to confirm substantial equivalence.

It has been demonstrated that the XO Cross is comparable to the predicate device in the following manner:

- Same intended use
- Same indications for use
- Same fundamental scientific technology
- Same or similar material properties
- Same operating principle
- Same or similar performance specifications
- Same or similar patient-user interface

<b>Table 1: Substantial Equivalence Comparison Chart</b>		
	<b>Predicate – K082561 (Quick-Cross Catheter)</b>	<b>Subject Device: XO Cross Catheter</b>
<b>Ind. for Use</b>	Quick-Cross Extreme Support Catheters are intended to guide and support a guidewire during access of the vasculature, allow for wire exchanges and provide a conduit for the delivery of saline solutions or diagnostic contrast agents.	The XO Cross is a support catheter intended to guide and support a guidewire during access of the peripheral vasculature, allow for wire exchanges and provide a conduit for the delivery of saline solutions or diagnostic contrast agents.
<b>Classification Name</b>	Cardiovascular Device – Percutaneous Catheter 21 CFR §870.1250 Product Code: DQY Class II	Same
<b>Single Use</b>	Yes	Same
<b>Fundamental Scientific Technology</b>	Single	Same
<b>Prescription (Rx Only)</b>	Yes	Same
<b>Anatomical Access</b>	Peripheral Vasculature	Same
<b>Design</b>	Single Lumen SS braided shaft w/ straight or angled tip. Distal 40 cm coated with hydrophilic coating.	Single Lumen metal alloy hypo-tube shaft w/ tapered tip and polymer jacket.
<b>Effective Length (cm)</b>	65, 90, 135, 150	90, 135, 150, 175
<b>Catheter Sizes</b>	4Fr	2Fr - 4Fr
<b>Distal Tip Profile</b>	1.9 Fr, 2.1Fr, 3.2Fr	1.6Fr, 1.9Fr, 3.2Fr
<b>Shaft Outer Diameter</b>	0.034", 0.038", 0.053"	0.029", 0.037", 0.051"

<b>Table 1: Substantial Equivalence Comparison Chart</b>		
	<b>Predicate – K082561 (Quick-Cross Catheter)</b>	<b>Subject Device: XO Cross Catheter</b>
<b>Visibility</b>	3 radiopaque markers	Radiopaque catheter body, 40% tungsten loading polymer tip
<b>Guidewire Compatibility</b>	0.014", 0.018", 0.035"	Same
<b>Sheath / Introducer Compatibility</b>	4 Fr, 5 Fr	4Fr
<b>Max Infusion Pressure</b>	300 psi, 500psi	Tested for manual infusion, not for use with power injectors.
<b>Sterility</b>	Sterile – EO	Same
<b>Biocompatibility</b>	ISO 10993	Same

**Functional/Safety Testing:**

The following functional tests were performed. All data met pre-determined acceptance criteria.

- **Biocompatibility** – Biocompatibility of the complete and finished *XO Cross* catheter has been verified according to the requirements and testing prescribed in ISO 10993-1 and in accordance with FDA guidance document "Use of International Standard ISO 10993-1" for an external communicating device with limited exposure (<24hrs) to circulating blood. Per ISO 10993-1, testing included the following:
  - *Cytotoxicity*
  - *Irritation/ Intracutaneous Toxicity*
  - *Sensitization*
  - *Systemic Injection*
  - *Material Mediated Pyrogenicity*
  - *Hemolysis Complete*
  - *Complement Activation*
  - *Thrombogenicity*
- **Design Verification** –The *XO Cross* models all meet or exceeded both Transit Scientifics in-house requirements, and requirements listed in ISO 10555-1. Packaging integrity was validated in conjunction with the sterilization studies.

**Conclusion:**

The *XO Cross* support catheter is substantially equivalent to the cited predicate device. Additionally, the *XO Cross* support catheter met all acceptance criteria to confirm substantial equivalence.